Laboratory Corp. of America Holdings  

(Public, NYSE:LH)   Watch this stock  
Find more results for LH
-0.40 (-0.29%)
After Hours: 137.60 0.00 (0.00%)
Jul 27, 4:33PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 134.90 - 139.80
52 week 97.79 - 139.80
Open 138.01
Vol / Avg. 1.32M/960,522.00
Mkt cap 14.11B
P/E 23.79
Div/yield     -
EPS 5.78
Shares 102.40M
Beta 0.88
Inst. own 96%
Jul 27, 2016
Q2 2016 Laboratory Corporation of America Holdings Earnings Release
Jul 27, 2016
Q2 2016 Laboratory Corporation of America Holdings Earnings Call - Webcast
Jun 14, 2016
Laboratory Corporation of America Holdings at William Blair Growth Stock Conference
May 12, 2016
Laboratory Corporation of America Holdings Annual Shareholders Meeting (Estimated)
May 11, 2016
Laboratory Corporation of America Holdings Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 6.78% 5.05%
Operating margin 12.75% 11.55%
EBITD margin - 18.14%
Return on average assets 4.52% 4.09%
Return on average equity 12.81% 11.37%
Employees 50,000 -
CDP Score - -


BURLINGTON, NC 27215-5837
United States - Map
+1-336-2291127 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company's LCD segment is an independent clinical laboratory business that consists of a network of approximately 40 primary laboratories and approximately 1,700 patient service centers (PSCs) along with a network of branches and STAT laboratories, which offer a menu of routine and frequently ordered tests. LCD offers a menu of over 4,700 tests, such as blood chemistry analyses, urinalyses, blood cell counts and thyroid tests. Its CDD segment offers drug development services, and provides a range of drug development solutions across the world, primarily to companies in the pharmaceutical and biotechnology industries.

Officers and directors

David P. King Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Glenn A. Eisenberg Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Deborah L. Keller Tanner Chief Executive Officer - Covance Drug Development
Age: 53
Bio & Compensation  - Reuters
Lisa J. Uthgenannt Chief Human Resource Officer
Age: 55
Bio & Compensation  - Reuters
Edward T. Dodson Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
Age: 62
Bio & Compensation  - Reuters
Lance V. Berberian Senior Vice President, Chief Information Officer
Age: 46
Bio & Compensation  - Reuters
F. Samuel Eberts III Senior Vice President, Chief Compliance Officer, Secretary, Chief Legal Officer
Age: 56
Bio & Compensation  - Reuters
Robert E. Mittelstaedt Jr. Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Kerrii B. Anderson Independent Director
Age: 58
Bio & Compensation  - Reuters
Jean-Luc Belingard Independent Director
Age: 67
Bio & Compensation  - Reuters